ZA201906696B - Liquid formulation of anti-tnf alpha antibody - Google Patents
Liquid formulation of anti-tnf alpha antibodyInfo
- Publication number
- ZA201906696B ZA201906696B ZA2019/06696A ZA201906696A ZA201906696B ZA 201906696 B ZA201906696 B ZA 201906696B ZA 2019/06696 A ZA2019/06696 A ZA 2019/06696A ZA 201906696 A ZA201906696 A ZA 201906696A ZA 201906696 B ZA201906696 B ZA 201906696B
- Authority
- ZA
- South Africa
- Prior art keywords
- liquid formulation
- tnf alpha
- alpha antibody
- antibody
- tnf
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170033188 | 2017-03-16 | ||
PCT/KR2018/003097 WO2018169348A1 (en) | 2017-03-16 | 2018-03-16 | Liquid formulation of anti-tnf alpha antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201906696B true ZA201906696B (en) | 2020-08-26 |
Family
ID=63522490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2019/06696A ZA201906696B (en) | 2017-03-16 | 2019-10-10 | Liquid formulation of anti-tnf alpha antibody |
Country Status (15)
Country | Link |
---|---|
JP (2) | JP7109849B2 (en) |
KR (2) | KR20180106974A (en) |
CN (1) | CN110621303A (en) |
AU (1) | AU2018236651B2 (en) |
BR (1) | BR112019019162A2 (en) |
CO (1) | CO2019010860A2 (en) |
MA (1) | MA46988A1 (en) |
MX (1) | MX2019010895A (en) |
MY (1) | MY197202A (en) |
NZ (1) | NZ757965A (en) |
PH (1) | PH12019502075A1 (en) |
RU (1) | RU2756619C2 (en) |
UA (1) | UA123847C2 (en) |
WO (1) | WO2018169348A1 (en) |
ZA (1) | ZA201906696B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11634485B2 (en) * | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
TW202102260A (en) * | 2019-03-21 | 2021-01-16 | 美商再生元醫藥公司 | Stabilized formulations containing anti-il-33 antibodies |
WO2021164717A1 (en) * | 2020-02-20 | 2021-08-26 | 百奥泰生物制药股份有限公司 | ANTI-TNF-α ANTIBODY PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI606840B (en) * | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | Improved high concentration anti-tnfα antibody liquid formulations |
UY34105A (en) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | STABLE LIQUID FORMULATION OF ETANERCEPT |
US10093728B2 (en) * | 2012-03-07 | 2018-10-09 | Cadila Healthcare Limited | Pharmaceutical formulations of TNF-alpha antibodies |
HUE049282T2 (en) * | 2012-09-07 | 2020-09-28 | Coherus Biosciences Inc | Stable aqueous formulations of adalimumab |
CA2898262A1 (en) | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
CN105025925A (en) | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | Anti-prolactin receptor antibody formulations |
WO2015134406A1 (en) | 2014-03-03 | 2015-09-11 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
CA2944330A1 (en) * | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
DK2946765T3 (en) * | 2014-05-23 | 2016-10-31 | Ares Trading Sa | Liquid pharmaceutical composition |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
HUP1400510A1 (en) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Pharmaceutical anti-tnfalpha antibody formulation |
EP3250598A1 (en) * | 2015-01-28 | 2017-12-06 | Mabxience S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
WO2016162819A1 (en) * | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
-
2018
- 2018-03-16 MA MA46988A patent/MA46988A1/en unknown
- 2018-03-16 MX MX2019010895A patent/MX2019010895A/en unknown
- 2018-03-16 RU RU2019130728A patent/RU2756619C2/en active
- 2018-03-16 JP JP2019551275A patent/JP7109849B2/en active Active
- 2018-03-16 KR KR1020180031016A patent/KR20180106974A/en active Application Filing
- 2018-03-16 BR BR112019019162A patent/BR112019019162A2/en active Search and Examination
- 2018-03-16 UA UAA201909838A patent/UA123847C2/en unknown
- 2018-03-16 WO PCT/KR2018/003097 patent/WO2018169348A1/en active Application Filing
- 2018-03-16 MY MYPI2019005331A patent/MY197202A/en unknown
- 2018-03-16 CN CN201880031705.6A patent/CN110621303A/en active Pending
- 2018-03-16 AU AU2018236651A patent/AU2018236651B2/en active Active
- 2018-03-16 NZ NZ757965A patent/NZ757965A/en unknown
-
2019
- 2019-09-12 PH PH12019502075A patent/PH12019502075A1/en unknown
- 2019-09-30 CO CONC2019/0010860A patent/CO2019010860A2/en unknown
- 2019-10-10 ZA ZA2019/06696A patent/ZA201906696B/en unknown
-
2020
- 2020-08-05 KR KR1020200098144A patent/KR102342292B1/en active IP Right Grant
-
2022
- 2022-05-06 JP JP2022076654A patent/JP2022097600A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP7109849B2 (en) | 2022-08-01 |
KR20180106974A (en) | 2018-10-01 |
KR20200096472A (en) | 2020-08-12 |
RU2019130728A (en) | 2021-04-16 |
CN110621303A (en) | 2019-12-27 |
NZ757965A (en) | 2022-07-01 |
AU2018236651A1 (en) | 2019-10-31 |
UA123847C2 (en) | 2021-06-09 |
JP2022097600A (en) | 2022-06-30 |
RU2019130728A3 (en) | 2021-04-16 |
JP2020510079A (en) | 2020-04-02 |
KR102342292B1 (en) | 2021-12-24 |
MA46988A1 (en) | 2020-06-30 |
BR112019019162A2 (en) | 2020-04-14 |
PH12019502075A1 (en) | 2020-09-14 |
WO2018169348A1 (en) | 2018-09-20 |
AU2018236651B2 (en) | 2020-12-10 |
MX2019010895A (en) | 2019-11-05 |
CO2019010860A2 (en) | 2020-01-17 |
MY197202A (en) | 2023-05-31 |
RU2756619C2 (en) | 2021-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282962A (en) | Anti-pd-1 antibodies and methods of use thereof | |
HK1244492A1 (en) | Anti-pd-1 antibodies and methods of use thereof | |
CL2016003250A1 (en) | Monoclonal antibodies against the epitope of her2 and its methods of use | |
HUE062927T2 (en) | Anti-tigit antibodies and methods of use thereof | |
HUE062436T2 (en) | Anti-trem2 antibodies and methods of use thereof | |
SG11201705585QA (en) | Anti-myostatin antibodies and methods of use | |
SG11201706505PA (en) | Stable liquid formulation for monoclonal antibodies | |
HK1251969A1 (en) | Anti-her2 antibodies and methods of use | |
HK1254743A1 (en) | Novel anti-claudin antibodies and methods of use | |
HK1259251A1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
IL286208A (en) | Humanized influenza monoclonal antibodies and methods of use thereof | |
IL268731A (en) | New uses of anti-sirpg antibodies | |
EP3394098A4 (en) | Anti-myostatin antibodies and methods of use | |
IL265438A (en) | Chimeric antigen receptors and compositions and methods of use thereof | |
PL3110447T3 (en) | Anti-egfr antibody and uses of same | |
SG11202001720RA (en) | Liquid dosage forms of imatinib | |
HUE059831T2 (en) | Application of liquids | |
ZA201906696B (en) | Liquid formulation of anti-tnf alpha antibody | |
ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
GB2548424B (en) | Liquid pharmaceutical composition of clonidine |